Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.eu.
Daiichi Sankyo Europe GmbH
Zielstattstr. 48
81379 Munich
Tel: +49 89 78080
Email: [email protected]
URL: www.daiichi-sankyo.eu
Sanofi
Sanofi is an R&D-driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Johnson & Johnson
Der pharmazeutische Geschäftsbereich Johnson & Johnson Innovative Medicine bildet zusammen mit der Medizintechniksparte Johnson & Johnson MedTech das globale Gesundheitsunternehmen Johnson & Johnson (J&J).
Bereits seit 1961 ist der Pharmabereich ein zentraler Bestandteil der Johnson & Johnson Unternehmensfamilie. Den Grundstein dafür legte der revolutionäre belgische Forscher Dr. Paul Janssen. J&J Innovative Medicine hat in Deutschland rund 1.000 Mitarbeitende und ist die Nummer 2 der forschenden Pharmaunternehmen. Der deutsche Firmensitz ist in Neuss, Nordrhein-Westfalen.
J&J investiert täglich weltweit etwa 37,1 Millionen US-Dollar in die Erforschung und Entwicklung neuer Medikamente, unter anderem in den Bereichen Onkologie, Immunologie und Neurowissenschaften. 15 Wirkstoffe des Unternehmens stehen auf der 23. WHO-Liste der unverzichtbaren Arzneimittel. 2024 wurden in Deutschland etwa 500.000 Patient:innen mit einem verschreibungspflichtigen Produkt von J&J behandelt.
Seit jeher orientiert sich das Handeln von J&J an klaren Grundsätzen. Das Firmencredo aus dem Jahr 1943 ist bis heute Grundlage aller unternehmerischen Entscheidungen: Die Bedürfnisse und das Wohlergehen der Menschen, die Medikamente und Services von J&J nutzen, stehen immer im Mittelpunkt.
J&J Innovative Medicine
Janssen-Cilag GmbH
Website: www.innovativemedicine.jnj.com/germany/
YouTube: J&J Innovative Medicine Deutschland
LinkedIn: J&J Innovative Medicine Deutschland
EM-159887
MSD
At MSD, known as Merck & Co., Inc., Rahway, NJ, in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
For more information, visit www.msd.de and connect with us on LinkedIn, Instagram and YouTube.
MSD Sharp & Dohme GmbH
Levelingstraße 4a, 81673 Müchen
E-Mail: [email protected]
Gilead/Kite
Kite, a Gilead Company, is based in Santa Monica, California, focused on achieving cures with cell therapy. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world.
About Gilead
Gilead Sciences, Inc. is a global biopharmaceutical company that has pursued and achieved breakthroughs in medicine over more than three decades, with the goal of creating a healthier world for all people. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
Pierre Fabre
Beauty care with four decades of experience in innovation, development, manufacture and
Marketing of oncologics. In 2022, the company devoted around 80% of its R&D spending to
Oncology, with a focus on targeted therapies.
Founded in 1962 in the south-west of France, the company manufactures 90% of its products in France and employs around 10,000 people worldwide. 86% of the company is owned by the Pierre Fabre Foundation, a government-approved non-profit foundation, and by its own employees under an international employee participation program.
Pierre Fabre Pharma GmbH
Neuer Messplatz 5, 79108 Freiburg
Tel: +49 (0)761 45261-0
Email: [email protected]
URL: www.pierre-fabre.com
Therakos
The THERAKOSTM CELLEX™ Photopheresis System is the world's only fully integrated and validated ECP system and is used by over 300 treatment centres in over 30 countries worldwide.
Beyond the THERAKOS™ CELLEX™ Photopheresis System, Therakos Healthcare Limited offers a comprehensive range of support services to help enable healthcare professionals (HCPs) to deliver ECP immunomodulation to patients.
Please see www.therakos.eu/isi for approved Indications and Important Safety Information.
To learn more about this product visit www.therakos.eu.
Therakos (UK) Ltd, 3 Lotus Park, The Causeway, Staines-Upon-Thames, Surrey, TW18 3AG, UK
Telephone +44 (0) 1784 636 700
Email address: [email protected]
Website: globalcorporate.therakos.com / Therakos.eu
Alexion
Alexion Pharma Germany GmbH
Landsberger Straße 300
D-80687 München
Tel: +49 (0) 89 45 70 91 300
Fax: +49 (0) 89 51 51 87 21
Email: [email protected]
Astellas
Astellas is a pharmaceutical company committed to turning innovative science into value for patients. Changing tomorrow is the ethos thaat guides everything we do.
Working at the forefront of healthcare change, Astellas invests in new medicines, technologies and therapeutic areas, and builds partnerships and networks with others who share our vision to improve the future of medicine.
Astellas Pharma GmbH
Ridlerstr. 57, 80339
München/Munich-Germany
URL: www.astellas.com/eu
Incyte
Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity.
Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For more information, visit Incyte.com and follow @Incyte.
Jazz Pharmaceuticals
Jazz Pharmaceuticals Germany GmbH, based in Munich, is part of a global biopharmaceutical company headquartered in Dublin. Our mission is to improve the lives of patients with serious diseases through innovative therapies—especially where treatment options are limited. With a science-driven and patient-centered approach, we deliver medicines that can make a real difference. Jazz focuses on the therapeutic areas of oncology and neuroscience.
Medac
At medac group, we believe that health is humanity's most valuable resource. Since 1970, our mission has been to improve patients' quality of life worldwide by making the best medical treatments available. As a globally operating pharmaceutical company headquartered in Germany, we provide high-quality medical treatments for patients worldwide in 91 countries. With more than 2.000 employees we are committed to improving human health.
All our products are manufactured in Germany and other European countries to the highest standards, utilizing our own logistics center and production sites, and subsequently distributed worldwide.
We are constantly working to improve authorized medicines and to develop innovative therapies in the fields of rheumatology, urology, hematology, and oncology. Part of our mission is to provide safe, high-quality and innovative original products, as well as generics and biosimilars. In this way, we make vital treatments accessible to those affected.
medac GmbH
Theaterstraße 6 22880
Wedel, Germany
URL: medac-group.com
Miltenyi Biomedicine
Miltenyi Biomedicine believe that cell and gene therapies can make a difference for patients worldwide. Our lead candidate is a CD20-CD19-directed tandem CAR-T cell treatment at pivotal stage trials in Europe and the USA. Committed to patient well-being, we strive to provide a sustainable and guaranteed supply, to treat patients promptly and improve access to cell therapy. A highly professional team with a proven track record in bringing new medicines to market ensures we maintain rigorous safety standards across all stages of our pharmaceutical advancements.
Miltenyi Biomedicine GmbH
Friedrich-Ebert-Str. 68
51429 Bergisch Gladbach
Germany
Neovii
Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.
Visit our booth to see our areas of interest, products and our research and development process.
Neovii's global headquarter:
Neovii Pharmaceuticals AG
Schlüsselstrasse 12
8645 Rapperswil-Jona
Switzerland
Phone: +41552100500
General Email: [email protected]
Medical Email: [email protected]
Biologics manufacturing site and German operations:
Neovii Biotech GmbH
Am Haag 6-7
82166 Gräfelfing/Germany
Phone: +49898988880
Eimail: [email protected]
Vertex Pharmaceuticals (Europe) Limited
Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It focuses on therapies for the underlying causes of diseases such as cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for other serious diseases like type 1 diabetes, APOL1-mediated kidney disease and IgA nephropathy.
https://www.vrtx.com/en-global/
Vertex Pharmaceuticals (Europe) Limited
2 Kingdom Street
London, W2 6BD
United Kingdom
AC-70-2500001 | August 2025
